Page last updated: 2024-09-04

atrasentan and Invasiveness, Neoplasm

atrasentan has been researched along with Invasiveness, Neoplasm in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P	1
Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F	1
Fischgräbe, J; Götte, M; Kersting, C; Kiesel, L; Smollich, M; Wülfing, P	1

Reviews

1 review(s) available for atrasentan and Invasiveness, Neoplasm

Article	Year
Targeting the endothelin axis in prostate carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:2 Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines	2012

Article

Year

Targeting the endothelin axis in prostate carcinoma.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:2

Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines

2012

Other Studies

2 other study(ies) available for atrasentan and Invasiveness, Neoplasm

Article	Year
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays	2004
Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast cancer research and treatment, 2008, Volume: 108, Issue:2 Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation	2008

Article

Year

Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.

Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays

2004

Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

Breast cancer research and treatment, 2008, Volume: 108, Issue:2

Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation

2008